| Patient | Emile Griffith |
|---|---|
| Date of birth | 1959-02-03 |
| Identifiers | MRN HR-BX005-SYN; SSN (made up) 000-05-6418 |
| Document date | 2026-05-19 |
| Author | Celeste Fairbanks-Ochieng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of memory loss and PTSD, seen the same day by cognitive neurology. [S]
Emile Griffith returns two weeks after intake with his care partner and is seen the same day by Dr. Haddad-Lindgren at the memory clinic. He had a brain MRI this morning. His intake blood count, metabolic panel, B12 and TSH were normal. He started sertraline 25 mg each morning after intake; he had mild nausea for three days, which has gone, and no dizziness or bleeding. The nightmares about the title fight still come most nights. His first session of cognitive processing therapy is booked for next week. He missed the physical therapy evaluation booked last week: the card was mislaid and nobody called to remind him. He has had no falls and has not travelled alone since intake. He has had no thoughts of suicide. [S]
| Element | Detail |
|---|---|
| MRI | Mild frontal-predominant atrophy; old right frontal injury; seven microbleeds; cavum septi pellucidi; hippocampi normal for age |
| CDR | Global 0.5, sum of boxes 2.0 |
| Sodium | 138 mmol/L two weeks into sertraline |
| Sertraline | 25 mg; nausea for three days, now gone |
| Safety | No thoughts of suicide; safety plan on the refrigerator |
| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Forgetfulness and slowness in finding words for names; no headaches, weakness, tremor or change in walking |
| Psychiatric | Positive | Nightmares most nights, guilt about the fight, mood low some days; no hallucinations, suspiciousness or thoughts of suicide |
| Gastrointestinal | Negative | Nausea in the first three days of sertraline, now gone; no diarrhea |
| Musculoskeletal | Negative | No falls |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sertraline 25 mg oral tablet, one tablet each morning | One tablet each morning | Oral route | 2026-05-05 to 2026-06-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-19 | Body height | 170 | cm | S |
| 2026-05-19 | Body weight | 73.8 | kg | S |
| 2026-05-19 | Body mass index (BMI) [Ratio] | 25.5 | kg/m2 | S |
| 2026-05-19 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-05-19 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-19 | Heart rate | 68 | /min | S |
| 2026-05-19 | Respiratory rate | 14 | /min | S |
| 2026-05-19 | Body temperature | 36.6 | Cel | S |
| 2026-05-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-19 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-19 | Clinical Dementia Rating scale [CDR] | 0.5 | {score} | S |
Vital signs recorded on 2026-05-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and warm; blood pressure 130/78 mmHg; pulse 68; weight 73.8 kg |
| Neurological | Cranial nerves normal; no rigidity, tremor or slowness; normal strength and reflexes; slightly wide-based gait with one side-step on tandem walking; no dysarthria |
| Mental status | Alert and courteous; needs cues to recall the plan from intake; tearful briefly when the fight is discussed; no psychotic symptoms; denies thoughts of suicide |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Memory loss and confusion over about a year, worse in recent months, reported by him and his care partner: repeating stories and questions, losing the thread of conversations, mixing up days, two missed appointments, and once getting lost changing trains on a familiar route; cause to be found | active | confirmed | R41.3 | S — Synthetic presenting problem anchored to the documented short-term memory problems; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age. |
| Post-traumatic stress disorder, chronic, after two index events (a title fight decades ago after which his opponent died, and a severe assault thirteen years ago): nightmares, unwanted images, avoidance of fight footage, guilt and self-blame, being on guard in crowds, poor sleep; PCL-5 41 | active | confirmed | F43.12 | S — Synthetic modern diagnosis at intake by clinical interview against DSM-5-TR criteria, anchored to his public words about lifelong nightmares; not a historical diagnosis. |
| Personal history of traumatic brain injury: repetitive head impacts over 112 professional bouts, and a severe head injury in an assault thirteen years ago with months in hospital | active | confirmed | Z87.820 | S — Synthetic coding of the documented career and assault. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA) | At diagnosis, then yearly, or sooner with change | Up to date | MoCA 22 at intake, with delayed recall helped by cues |
| Survey | Staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Completed today | Global CDR 0.5 (sum of boxes 2.0); independent in personal care; reminders for appointments and help with bills (Functional Activities Questionnaire 6) |
| Laboratory | Reversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearing and vision | Once at diagnosis | Up to date | Completed at intake: blood count, metabolic panel, B12 418 pg/mL and TSH 2.1, normal; PHQ-9 9; STOP-Bang 2 (low risk); whispered-voice test and near vision normal; no anticholinergic or sedating medicines |
| Imaging | Structural brain MRI | Once at diagnosis; repeat only with an atypical course or focal change | Completed today | Mild frontal-predominant atrophy; old right frontal encephalomalacia; seven microbleeds; cavum septi pellucidi; hippocampi normal for age; no infarct, mass or subdural collection |
| Survey | Neuropsychological testing | At diagnosis when the cause or stage is unclear; repeat in 12 to 18 months or with change | Ordered | Booked in three weeks |
| Laboratory | Alzheimer's disease biomarkers (blood, CSF or amyloid PET) | When the result would change diagnosis or management | Due | To be discussed with the testing results |
| Examination | Medicine review for anticholinergic, sedating and fall-risk drugs (Beers) | Every visit | Completed today | Sertraline 25 mg only; no anticholinergic, sedating or over-the-counter sleep medicines |
| Survey | Neuropsychiatric symptom screen (apathy, irritability, paranoia, impulsivity) | Every visit | Completed today | No apathy, irritability, paranoia or impulsive behavior |
| Survey | PHQ-9 with suicide-risk review (item 9 and structured questions) | Monthly during acute treatment; every visit during active treatment | Up to date | PHQ-9 9 at intake, item 9 scored 0; no thoughts of suicide today; next PHQ-9 at six weeks |
| Survey | PCL-5 | Baseline, then at each chronic-care visit during treatment; response judged after 8 to 12 weeks | Up to date | PCL-5 41 at intake; next at six weeks |
| Medication safety | Sertraline: nausea, sleep, falls, bleeding, and sodium (SSRIs can lower sodium in older adults) | Two weeks after starting and after each dose change; sodium at those points | Completed today | Two weeks on 25 mg: nausea resolved; no dizziness, falls or bleeding; sodium 138 mmol/L |
| Referral | Trauma-focused psychotherapy (cognitive processing therapy) | Weekly, about twelve sessions | Referred | With the clinic psychologist; first session next week |
| Examination | Fall risk (Timed Up and Go, gait and balance), STEADI | At diagnosis, yearly, and after any fall | Up to date | Timed Up and Go 13 seconds at intake; one fall on ice last winter; no fall since |
| Referral | Physical therapy for balance and strength | Once, after a Timed Up and Go above 12 seconds | Deferred | Deviation: the evaluation booked for last week was missed because the appointment card was mislaid and no reminder call was made. No fall has occurred, so no harm is known. Corrective action: rebooked at the first opening, in about five weeks, with a reminder call to him and his care partner and the date on the wall calendar |
| Examination | Driving safety | At diagnosis and each follow-up | Not indicated | He does not drive |
| Self-management | Travel, money and home safety | At diagnosis and each follow-up | Completed today | Travels with his care partner; no firearms; medicines kept by his care partner |
| Examination | Vascular risk factors (blood pressure, weight) | Every visit | Completed today | Blood pressure 130/78 mmHg; weight 73.8 kg |
Goal progress:
Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); STEADI (Stopping Elderly Accidents, Deaths and Injuries): Clinical Resources (2024)
Follow-up: Neuropsychological testing in three weeks. Six-week review with the results, PHQ-9 and PCL-5. Call the clinic or 988 at any time if thoughts of suicide arise. Next scheduled visit 2026-06-16: six-week review: neuropsychological testing, the diagnosis and the plan, PTSD treatment, safety and caregiver support. [S]